Study of Rituximab and Venetoclax in People With Newly Diagnosed Marginal Zone Lymphoma
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This study will help researchers understand how effective the combination of venetoclax and
rituximab is in treating MZL in people who have not received a previous treatment for their
cancer.